Evidence map›Paper›PMID 29226856›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis.

Mohammed Benlahfid, Wael Traboulsi, Frederic Sergent, Mohamed Benharouga, Khalid Elhattabi, Driss Erguibi, Mehdi Karkouri, Hicham Elattar, Abdelaziz Fadil, Yassine Fahmi and 2 more

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Mohammed BenlahfidLaboratory of Scientific and Clinical Researches in Cancerous Pathologies, Faculty of Medicine and Pharmacy, University Hassan II of Casablanca, Casablanca, Morocco.
Wael TraboulsiInstitut National de la Santé et de la Recherche Médicale U1036, Grenoble, France.
Frederic SergentInstitut National de la Santé et de la Recherche Médicale U1036, Grenoble, France.
Mohamed BenharougaUniversity Grenoble-Alpes, Grenoble, France.
Khalid ElhattabiLaboratory of Scientific and Clinical Researches in Cancerous Pathologies, Faculty of Medicine and Pharmacy, University Hassan II of Casablanca, Casablanca, Morocco.
Driss ErguibiLaboratory of Scientific and Clinical Researches in Cancerous Pathologies, Faculty of Medicine and Pharmacy, University Hassan II of Casablanca, Casablanca, Morocco.
Mehdi KarkouriIbn Rochd University Hospital of Casablanca, University Hassan II of Casablanca, Casablanca, Morocco.
Hicham ElattarLaboratory of anatomopathology Moulay Driss 1e⁢r, Casablanca, Morocco.
Abdelaziz FadilIbn Rochd University Hospital of Casablanca, University Hassan II of Casablanca, Casablanca, Morocco.
Yassine FahmiIbn Rochd University Hospital of Casablanca, University Hassan II of Casablanca, Casablanca, Morocco.
Touria AboussaouiraLaboratory of Scientific and Clinical Researches in Cancerous Pathologies, Faculty of Medicine and Pharmacy, University Hassan II of Casablanca, Casablanca, Morocco.
Nadia AlfaidyInstitut National de la Santé et de la Recherche Médicale U1036, Grenoble, France.
University of Hassan II Casablanca · MAUniversité Grenoble Alpes · FRInserm · FRLaboratoire de Chimie et Biologie des Métaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe highest risk factor for mortality among malignant tumors is metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor which biological activity is mediated via two G protein-coupled receptors, prokineticin receptor1 (PROKR1) and PROKR2. Recent studies suggested that EG-VEGF expression is deregulated in multiple cancers including colorectal cancer (CRC).

methodsUsing distinctive CRC and peritoneal carcinomatosis (PC) cohorts and a corresponding control cohort, we determined the circulating levels of EG-VEGF and its in situ expression, and that of its related receptors.

resultsCirculating EG-VEGF levels were significantly increased in patients with metastatic PC compared to CRC and control patients (p< 0.05). Furthermore, according to clinicopathologic examinations, local EG-VEGF expression correlated with higher tumor and nodal stages (p< 0.001) of CRC. EG-VEGF and PROKR2 were highly expressed in colorectal primary lesions compared to positive controls. PROKR1 expression was lower and did not change in tumor specimens. Also, EG-VEGF and its receptor PROKR2 were differentially expressed in the colorectal primary lesions and in the control groups.

conclusionAltogether these findings suggest that EG-VEGF/receptors system might be an important actor in the CRC progression into PC and might be involved in the ability of tumor cells to invade other organs. Circulating EG-VEGF could be proposed as a prognostic marker in human CRC and its progression into PC.

Indexed as

AdolescentAdultAgedColorectal NeoplasmsDisease ProgressionFemaleHumansImmunohistochemistryMaleMiddle AgedPeritoneal NeoplasmsReceptors, G-Protein-CoupledReceptors, PeptideRisk FactorsVascular Endothelial Growth Factor, Endocrine-Gland-DerivedYoung AdultPROKR1 protein, humanPROKR2 protein, humanReceptors, G-Protein-CoupledReceptors, PeptideVascular Endothelial Growth Factor, Endocrine-Gland-Derivedcolorectal cancerEG-VEGFperitoneal carcinomatosisProkineticin

Identifiers

PMID29226856
PMCPMC13078283
OpenAlexW2775689206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.